User profiles for "author:Zahi Touma"

Zahi Touma

Associate Professor of Medicine, University of Toronto
Verified email at uhn.ca
Cited by 7412

2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus

M Aringer, K Costenbader, D Daikh… - Arthritis & …, 2019 - Wiley Online Library
Objective To develop new classification criteria for systemic lupus erythematosus (SLE)
jointly supported by the European League Against Rheumatism (EULAR) and the American …

Mycophenolate mofetil for induction treatment of lupus nephritis: a systematic review and metaanalysis

Z Touma, DD Gladman, MB Urowitz, J Beyene… - The Journal of …, 2011 - jrheum.org
Objective. To systematically review the efficacy and safety of mycophenolic acid and
mycophenolate mofetil (MMF) compared to cyclophosphamide (CYC) for the induction …

Current and future therapies for SLE: obstacles and recommendations for the development of novel treatments

Z Touma, DD Gladman - Lupus science & medicine, 2017 - lupus.bmj.com
SLE is a serious, debilitating autoimmune disease that affects various organs and body
systems. Of all the heterogeneous autoimmune diseases, SLE is perhaps the most …

Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2 …

RF van Vollenhoven, BH Hahn, GC Tsokos… - The Lancet, 2018 - thelancet.com
Background Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23
and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's …

Risk of cardiovascular morbidity in patients with psoriatic arthritis: a meta‐analysis of observational studies

ARI Polachek, Z Touma, M Anderson… - Arthritis care & …, 2017 - Wiley Online Library
Objective To assess the magnitude of risk of cardiovascular and cerebrovascular morbidity
in patients with psoriatic arthritis (PsA) compared with the general population through a …

Apoptotic cell–induced AhR activity is required for immunological tolerance and suppression of systemic lupus erythematosus in mice and humans

R Shinde, K Hezaveh, MJ Halaby, A Kloetgen… - Nature …, 2018 - nature.com
The transcription factor AhR modulates immunity at multiple levels. Here we report that
phagocytes exposed to apoptotic cells exhibited rapid activation of AhR, which drove …

How do patients with newly diagnosed systemic lupus erythematosus present? A multicenter cohort of early systemic lupus erythematosus to inform the development …

M Mosca, KH Costenbader, SR Johnson… - Arthritis & …, 2019 - Wiley Online Library
Objective Systemic lupus erythematosus (SLE) presents with nonspecific signs and
symptoms that are also found in other conditions. This study aimed to evaluate …

Time to recovery from proteinuria in patients with lupus nephritis receiving standard treatment

Z Touma, MB Urowitz, D Ibañez… - The Journal of …, 2014 - jrheum.org
Objective. The recovery time from abnormal levels of proteinuria with standard treatment in
longitudinal studies of patients with systemic lupus erythematosus has not been well …

Prevalence and metric of depression and anxiety in systemic lupus erythematosus: a systematic review and meta-analysis

AT Moustafa, M Moazzami, L Engel, E Bangert… - Seminars in arthritis and …, 2020 - Elsevier
Objectives To systematically review and synthesize literature on 1) the overall prevalence of
depression and anxiety in SLE patients in identified studies, and 2) the pooled prevalence …

What is the prevalence of cognitive impairment in lupus and which instruments are used to measure it? A systematic review and meta-analysis

H Al Rayes, C Tani, A Kwan, S Marzouk… - Seminars in arthritis and …, 2018 - Elsevier
Objectives To systematically review the literature on the prevalence of Cognitive Dysfunction
(CD) in SLE patients in studies that used a specified neuropsychological instrument …